BALCHEM CORP — fact timeline

BALCHEM CORP shareholders approved Advisory approval of the compensation of the Company's named executive officers at the 2026-06-18 meeting.

“Advisory approval of the compensation of the Company’s named executive officers: Votes For Votes Against Abstained Broker Non-Votes 26,636,456 554,019 38,037 1,934,748”

BALCHEM CORP shareholders approved Ratification of the appointment of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-18 meeting.

“The ratification of the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: Votes For Votes Against Abstained 28,671,701 457,235 24,324”

BALCHEM CORP shareholders approved Election of two Class 3 director nominees to the Board of Directors to serve until the Annual Meeting of Shareholders in 2029 and until their successors are duly elected and qualified at the 2026-06-18 meeting.

“The election of two Class 3 director nominees to the Board of Directors to serve until the Annual Meeting of Shareholders in 2029 and until their successors are duly elected and qualified: Director Nominee Votes For Votes Against Abstained Broker Non-Votes David Fischer 25,318,402 1,877,390 22,720 1,934,748 Daniel Knutson 26,755,996 439,880 22,636 1,934,748”

BALCHEM CORP reported first quarter ended March 31, 2026 results: revenue $270.7 million, net income $40.3 million, EPS $1.25 per diluted share.

“First Quarter 2026 Financial Highlights: • Net sales were $270.7 million, an increase of 8.1% compared to the prior year quarter. • GAAP net earnings were $40.3 million, an increase of 8.7% from the prior year quarter. • Adjusted EBITDA was $74.3 million, an increase of 12.1% from the prior year quarter. • GAAP earnings per share was $1.25 compared to $1.13 in the prior year quarter and adjusted earnings per share (a) was $1.33 compared to $1.22 in the prior year quarter.”

William A. Backus departed as Vice President and Chief Accounting Officer at BALCHEM CORP.

“William A. Backus, Vice President and Chief Accounting Officer, has notified the Company of his intent to retire from his position on March 31, 2026.”

Joyce Lee resigned as Director at BALCHEM CORP.

“On October 16, 2024, the Corporate Governance and Nominating Committee of the Balchem Corporation (“Balchem”) Board of Directors (the “Board”) accepted the resignation of Joyce Lee as a Director.”

BALCHEM CORP reported financial results for the quarter ended March 31, 2024.

“On May 3, 2024, Balchem Corporation, reported earnings for the quarter ended March 31, 2024, and certain other information. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1.”

Jonathan H. Griffin changed role as Senior Vice President, Corporate Development at BALCHEM CORP.

“On March 27, 2024, Balchem Corporation (the “Company”) announced that Jonathan H. Griffin, Senior Vice President and General Manager, Animal Nutrition and Health, would be moving into the role of Senior Vice President, Corporate Development, effective immediately.”

BALCHEM CORP reported FY 2023 (year ended December 31, 2023) results: revenue $922.4 million, net income $108.5 million, EPS $3.35.

“Full Year 2023 Financial Highlights: • GAAP net earnings were $108.5 million, an increase of 3.0% from the prior year. These net earnings resulted in GAAP earnings per share of $3.35 compared to $3.25 in the prior year.”

BALCHEM CORP reported Q4 2023 (three months ended December 31, 2023) results: revenue $228.7 million, net income $26.6 million, EPS $0.82.

“The Company reported quarterly net sales of $228.7 million, quarterly net earnings of $26.6 million, adjusted EBITDA (a) of $55.4 million, and free cash flow (a) of $56.0 million.”

BALCHEM CORP reported Q3 2023 results: revenue $229.9 million, net income $29.1 million, EPS $0.90.

“Balchem Corporation (NASDAQ: BCPC) reported today third quarter net sales of $229.9 million for 2023, compared to net sales of $244.3 million in the prior year quarter. Third quarter net earnings were $29.1 million for 2023, compared to net earnings of $25.2 million for the third quarter 2022.”

Monica Vicente was elected as Director at BALCHEM CORP.

“On September 1, 2023, the Board of Directors (the “Board”) of Balchem Corporation (the “Company”) elected Olivier Rigaud and Monica Vicente to the Board, effective as of September 6, 2023, respectively.”

Olivier Rigaud was elected as Director at BALCHEM CORP.

“On September 1, 2023, the Board of Directors (the “Board”) of Balchem Corporation (the “Company”) elected Olivier Rigaud and Monica Vicente to the Board, effective as of September 6, 2023, respectively.”

BALCHEM CORP reported the quarter ended June 30, 2023 results: revenue $231.3 million, net income $30.1 million, EPS $0.93.

“• Second quarter net sales were $231.3 million, a decrease of $5.4 million, or 2.3%, compared to the prior year. • Record quarterly adjusted EBITDA was $59.1 million, an increase of $2.6 million, or 4.6%, from the prior year. • GAAP net earnings were $30.1 million, an increase of $0.3 million, or 1.1% from the prior year. These net earnings resulted in GAAP earnings per share of $0.93.”

BALCHEM CORP shareholders approved Approval of the Amended and Restated 2017 Omnibus Incentive Plan. at the 2023-06-22 meeting.

“Approval of the Amended and Restated 2017 Omnibus Incentive Plan: Votes For Votes Against Abstained Broker Non-Votes 26,513,603 1,062,001 31,506 1,553,008”

BALCHEM CORP shareholders approved Advisory vote on whether "Say-on-Pay" should occur every one, two or three years. at the 2023-06-22 meeting.

“Advisory vote on whether "Say-on-Pay" should occur every one, two or three years: 1 Year 2 Years 3 Years Abstained 26,779,710 35,841 770,266 21,293”

BALCHEM CORP shareholders approved Advisory approval of the compensation of the Company's named executive officers. at the 2023-06-22 meeting.

“Advisory approval of the compensation of the Company's named executive officers: Votes For Votes Against Abstained Broker Non-Votes 17,875,728 6,857,673 2,873,709 1,553,008”

BALCHEM CORP shareholders approved Ratification of the appointment of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. at the 2023-06-22 meeting.

“Ratification of the appointment of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023: Votes For Votes Against Abstained 28,779,713 368,507 11,898”

BALCHEM CORP shareholders approved Election of one Class 3 director nominee to the Board of Directors of Balchem Corporation to serve until the 2026 Annual Meeting of Shareholders and until his successor is duly elected and qualified. at the 2023-06-22 meeting.

“Election of one Class 3 director nominee to the Board of Directors of Balchem Corporation to serve until the 2026 Annual Meeting of Shareholders and until his successor is duly elected and qualified: Director Nominee Votes For Votes Against Abstained Broker Non-Votes David Fischer 22,999,214 1,828,707 2,779,189 1,553,008”

BALCHEM CORP reported the year ended December 31, 2022 results: revenue $942.4 million, net income $105.4 million, EPS $3.25.

“Balchem Corporation also reported for the full year 2022 net sales of $942.4 million, compared to $799.0 million for 2021. Full year 2022 net earnings were $105.4 million, compared to net earnings of $96.1 million for 2021, with adjusted net earnings of $130.5 million, compared to $116.6 million in the prior year.”

BALCHEM CORP reported the quarter ended December 31, 2022 results: revenue $232.5 million, net income $21.4 million, EPS $0.66.

“Balchem Corporation (NASDAQ: BCPC) reported today fourth quarter net sales of $232.5 million for 2022, compared to net sales of $213.1 million for the fourth quarter 2021. Fourth quarter net earnings were $21.4 million for 2022, compared to net earnings of $24.9 million for the fourth quarter 2021, with adjusted net earnings (a) of $30.3 million, compared to $27.8 million in the prior year quarter.”

BALCHEM CORP: Amended and restated By-laws to enhance procedural mechanics for shareholder nominations and proxies, including compliance with Rule 14a-19 (effective 2022-12-05).

“On and effective December 5, 2022, the Board of Directors (the “Board”) of Balchem Corporation (the “Company”) amended and restated the Company’s By-laws as follows: • Article II (Meetings of Shareholders), Section 6 (Advance Notice of Shareholder Nominations and Proposals) and Section 10 (Proxies) – enhanced procedural mechanics and made other revisions with respect to the notification and other requirements related to nominations of directors and solicitations of proxies, including requiring compliance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended.”

BALCHEM CORP reported the quarter ended September 30, 2022 results: revenue $244.3 million, net income $25.2 million, EPS $0.78.

“in such a filing. --- EX-99.1 (EX-99.1) --- Human Nutrition & Health | Animal Nutrition & Health | Specialty Products Balchem Corporation Reports Third Quarter Sales of $244.3 Million, Net Earnings of $25.2 Million, GAAP EPS of $0.78, and Adjusted EPS of $1.00 Montvale, NJ, November 4, 2022 - Balchem Corporation (NASDAQ: BCPC) reported today third quarter net”

James C. Hyde departed as Senior Vice President and General Manager, Human Nutrition & Health at BALCHEM CORP.

“James C. Hyde, Senior Vice President and General Manager, Human Nutrition & Health, has notified the Company of his intent to retire from his role and that he will step down upon the appointment of his successor.”

Mark Stach departed as General Counsel and Secretary at BALCHEM CORP.

“On June 7, 2022, Balchem Corporation (the “ Company ”) announced that Mark Stach, General Counsel and Secretary of the Company, has notified the Company of his intent to retire and will step down upon the appointment of his successor.”